Liquid nitrogen spray cryotherapy-based multimodal endoscopic management of dysplastic Barrett's esophagus and early esophageal neoplasia: retrospective review and long-term follow-up at an academic tertiary care referral center. Issue 4 (7th January 2020)

• Record Type: Journal Article
• Authors: Kaul, Vivek; Bittner, Krystle; Ullah, Asad; Kothari, Shivangi
• Is Part Of: Diseases of the esophagus. Volume 33:Issue 4(2020)
• Publication Date: 2020-01-07
• Subjects: Barrett's esophagus -- cryotherapy -- dysplasia -- endoscopic ablation -- esophageal adenocarcinoma; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1093/dote/doz095
• Languages: English
• ISSNs: 1120-8694

Abstract

Summary: Background: Endoscopic eradication therapy of dysplastic Barrett's esophagus (BE) and early esophageal neoplasia has emerged as an effective treatment option. Data for the role of spray cryotherapy (SCT) in this setting is relatively limited. Objective: To evaluate the safety and long-term outcomes of SCT-based multimodal therapy in the management of dysplastic BE and early esophageal neoplasia. Design: Single-center, retrospective, cohort study. Setting: Academic, tertiary care center between August 2008 and February 2019. Methods: A retrospective chart review was conducted of the prospectively maintained endoscopic cryotherapy database at our center. Fifty-seven patients were identified who underwent SCT treatment for dysplastic BE and esophageal or Gastro-esophageal (GE) junction adenocarcinoma during the study period. Primary outcome was complete eradication of intestinal metaplasia (CE-IM); secondary outcome was complete eradication of dysplasia (CE-D). Results: A total of 171 SCT procedures were performed in 57 patients. The majority of patients were male (89.5%) with long-segment BE (93%; mean segment length 6.2 cm). Complete follow-up data was available for 56 of these 57 patients. 43.9% (25/57) of patients underwent radiofrequency ablation (RFA) during the course of treatment (e.g. after initiating SCT). 33.3% of patients (19/57) were RFA failures prior to SCT. Additionally, 68.4% (39/57) of patients underwent endoscopic resection (EMR) prior to SCT as part of our multimodal approach to treatment of BE dysplasia/neoplasia. Four patients (7%) are currently undergoing active ablation and/or EMR treatment. CE-IM was achieved in 75% (39/52) of patients, and CE-D in 98.1% (51/52). Mean duration of overall follow-up was 4.8 years, with mean CE-IM durability of 2.6 years. Limitations: Single-center only, retrospective study design. Conclusion: SCT-based multimodal endoscopic therapy can achieve very high CE-IM (75%) and CE-D (>98%) rates in a high-risk population with esophageal dysplasia and/or neoplasia.